Trade CNS Pharmaceuticals, Inc. - CNSP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.0322 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.01 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 0.35 |
Open* | 0.3651 |
1-Year Change* | -65.45% |
Day's Range* | 0.345 - 0.3733 |
52 wk Range | 0.16-1.38 |
Average Volume (10 days) | 92.00K |
Average Volume (3 months) | 3.97M |
Market Cap | 8.41M |
P/E Ratio | -100.00K |
Shares Outstanding | 40.03M |
Revenue | N/A |
EPS | -0.35 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Mar 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 0.3733 | 0.0083 | 2.27% | 0.3650 | 0.3733 | 0.3450 |
Mar 27, 2024 | 0.3500 | -0.0050 | -1.41% | 0.3550 | 0.3686 | 0.3350 |
Mar 26, 2024 | 0.3597 | 0.0104 | 2.98% | 0.3493 | 0.3626 | 0.3391 |
Mar 25, 2024 | 0.3450 | -0.0100 | -2.82% | 0.3550 | 0.3625 | 0.3450 |
Mar 22, 2024 | 0.3478 | 0.0028 | 0.81% | 0.3450 | 0.3719 | 0.3388 |
Mar 21, 2024 | 0.3450 | -0.0111 | -3.12% | 0.3561 | 0.3691 | 0.3450 |
Mar 20, 2024 | 0.3568 | 0.0118 | 3.42% | 0.3450 | 0.3750 | 0.3410 |
Mar 19, 2024 | 0.3362 | -0.0248 | -6.87% | 0.3610 | 0.3695 | 0.3288 |
Mar 18, 2024 | 0.3644 | -0.0048 | -1.30% | 0.3692 | 0.3692 | 0.3550 |
Mar 15, 2024 | 0.3807 | 0.0357 | 10.35% | 0.3450 | 0.3807 | 0.3450 |
Mar 14, 2024 | 0.3786 | 0.0036 | 0.96% | 0.3750 | 0.3850 | 0.3161 |
Mar 13, 2024 | 0.3807 | -0.0446 | -10.49% | 0.4253 | 0.4253 | 0.3761 |
Mar 12, 2024 | 0.4150 | -0.0219 | -5.01% | 0.4369 | 0.4380 | 0.4099 |
Mar 11, 2024 | 0.4260 | -0.0152 | -3.45% | 0.4412 | 0.4651 | 0.4250 |
Mar 8, 2024 | 0.4176 | 0.0026 | 0.63% | 0.4150 | 0.4420 | 0.3903 |
Mar 7, 2024 | 0.4339 | -0.0211 | -4.64% | 0.4550 | 0.4550 | 0.3858 |
Mar 6, 2024 | 0.4350 | 0.0400 | 10.13% | 0.3950 | 0.4450 | 0.3750 |
Mar 5, 2024 | 0.3672 | -0.0044 | -1.18% | 0.3716 | 0.4025 | 0.3450 |
Mar 4, 2024 | 0.3360 | -0.0056 | -1.64% | 0.3416 | 0.3710 | 0.3150 |
Mar 1, 2024 | 0.3162 | 0.0412 | 14.98% | 0.2750 | 0.3316 | 0.2650 |
CNS Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 14.0273 | 9.45461 | 3.83298 | 7.16863 | 0.21511 |
Selling/General/Admin. Expenses, Total | 4.68084 | 4.39287 | 1.97864 | 0.86052 | 0.18247 |
Research & Development | 9.34645 | 5.06173 | 1.85433 | 0.02127 | 0.03264 |
Unusual Expense (Income) | 0 | 6.28684 | 0 | ||
Operating Income | -14.0273 | -9.45461 | -3.83298 | -7.16863 | -0.21511 |
Interest Income (Expense), Net Non-Operating | -0.00929 | -0.00326 | -0.04423 | -0.0467 | -0.00426 |
Other, Net | 0 | -0.17657 | 0 | ||
Net Income Before Taxes | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Net Income After Taxes | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Net Income Before Extra. Items | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Total Extraordinary Items | 0 | ||||
Net Income | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Income Available to Common Excl. Extra. Items | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Income Available to Common Incl. Extra. Items | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Diluted Net Income | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Diluted Weighted Average Shares | 26.3533 | 16.6184 | 13.6479 | 15.712 | 15.712 |
Diluted EPS Excluding Extraordinary Items | -0.53263 | -0.56912 | -0.28409 | -0.47046 | -0.01396 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -0.53263 | -0.56912 | -0.28409 | -0.07033 | -0.01396 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 2.78177 | 2.79292 | 3.8134 | 3.81132 | 3.60966 |
Selling/General/Admin. Expenses, Total | 1.26041 | 0.89633 | 1.23539 | 1.14634 | 1.40278 |
Research & Development | 1.52136 | 1.89658 | 2.57802 | 2.66498 | 2.20687 |
Operating Income | -2.78177 | -2.79292 | -3.8134 | -3.81132 | -3.60966 |
Interest Income (Expense), Net Non-Operating | -0.00257 | -0.00224 | -0.00095 | -0.00235 | -0.00375 |
Net Income Before Taxes | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Net Income After Taxes | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Net Income Before Extra. Items | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Net Income | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Income Available to Common Excl. Extra. Items | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Income Available to Common Incl. Extra. Items | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Diluted Net Income | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Diluted Weighted Average Shares | 38.8083 | 27.8385 | 27.4438 | 25.4327 | 24.6644 |
Diluted EPS Excluding Extraordinary Items | -0.07175 | -0.10041 | -0.13899 | -0.14995 | -0.1465 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.07175 | -0.10041 | -0.13899 | -0.14995 | -0.1465 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 7.47745 | 15.4958 | 7.89391 | 0.58813 | 0.16219 |
Cash and Short Term Investments | 5.00452 | 14.0395 | 7.24129 | 0.28274 | 0.11054 |
Cash & Equivalents | 5.00452 | 14.0395 | 7.24129 | 0.28274 | 0.11054 |
Prepaid Expenses | 2.47293 | 1.45635 | 0.65262 | 0.033 | 0.05165 |
Other Current Assets, Total | 0 | 0.2724 | 0 | ||
Total Assets | 8.75739 | 15.8534 | 7.91208 | 0.68333 | 0.16219 |
Other Long Term Assets, Total | 1.26383 | 0.33414 | 0 | 0.0952 | 0 |
Total Current Liabilities | 2.13557 | 1.90543 | 0.311 | 1.23263 | 0.22073 |
Accounts Payable | 1.52282 | 0.94633 | 0.24367 | 0.12807 | 0.0425 |
Payable/Accrued | 0 | 0.04583 | 0.00079 | 0.015 | |
Accrued Expenses | 0.22495 | 0.5198 | 0.0215 | 0.0236 | 0.0414 |
Notes Payable/Short Term Debt | 0.38779 | 0.43929 | 0 | 0.31692 | 0.12183 |
Other Current Liabilities, Total | 0 | 0.76325 | 0 | ||
Total Liabilities | 2.13557 | 1.90543 | 0.311 | 1.23263 | 0.22073 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 6.62182 | 13.948 | 7.60108 | -0.5493 | -0.05853 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.02793 | 0.02386 | 0.01645 | 0.0127 | 0.01027 |
Additional Paid-In Capital | 41.5768 | 34.8705 | 19.0731 | 7.04927 | 0.15056 |
Retained Earnings (Accumulated Deficit) | -34.9829 | -20.9463 | -11.4885 | -7.61126 | -0.21936 |
Total Liabilities & Shareholders’ Equity | 8.75739 | 15.8534 | 7.91208 | 0.68333 | 0.16219 |
Total Common Shares Outstanding | 27.9272 | 23.8561 | 16.4502 | 15.712 | 15.712 |
Property/Plant/Equipment, Total - Net | 0.01611 | 0.02343 | 0.01817 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 14.7332 | 7.47745 | 11.1558 | 13.8835 | 12.7864 |
Cash and Short Term Investments | 12.4405 | 5.00452 | 8.32622 | 6.88557 | 11.0752 |
Cash & Equivalents | 12.4405 | 5.00452 | 8.32622 | 6.88557 | 11.0752 |
Total Receivables, Net | 3.70177 | 0.13265 | |||
Accounts Receivable - Trade, Net | 0.13265 | 0.13265 | |||
Prepaid Expenses | 2.29267 | 2.47293 | 2.82961 | 3.29615 | 1.57852 |
Total Assets | 15.8719 | 8.75739 | 11.5075 | 14.2385 | 13.1446 |
Property/Plant/Equipment, Total - Net | 0.01273 | 0.01611 | 0.01753 | 0.0209 | 0.02411 |
Other Long Term Assets, Total | 1.12596 | 1.26383 | 0.33414 | 0.33414 | 0.33414 |
Total Current Liabilities | 1.0693 | 2.13557 | 2.40743 | 1.83075 | 1.90176 |
Accounts Payable | 0.48972 | 1.52282 | 1.46157 | 0.89249 | 1.05768 |
Accrued Expenses | 0.30701 | 0.22495 | 0.90122 | 0.76068 | 0.53494 |
Notes Payable/Short Term Debt | 0.27257 | 0.38779 | 0.04463 | 0.17758 | 0.30913 |
Total Liabilities | 1.0693 | 2.13557 | 2.40743 | 1.83075 | 1.90176 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 14.8026 | 6.62182 | 9.10007 | 12.4078 | 11.2429 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.04003 | 0.02793 | 0.02746 | 0.02738 | 0.02535 |
Additional Paid-In Capital | 52.5298 | 41.5768 | 41.2604 | 40.7538 | 35.7772 |
Retained Earnings (Accumulated Deficit) | -37.7673 | -34.9829 | -32.1878 | -28.3734 | -24.5597 |
Total Liabilities & Shareholders’ Equity | 15.8719 | 8.75739 | 11.5075 | 14.2385 | 13.1446 |
Total Common Shares Outstanding | 40.0325 | 27.9272 | 27.4607 | 27.3795 | 25.3528 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Cash From Operating Activities | -13.5383 | -7.31802 | -3.55347 | -0.71639 | -0.1122 |
Non-Cash Items | 1.72384 | 1.29498 | 0.7474 | 6.59174 | 0.05992 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Cash Interest Paid | 0.00977 | 0.00171 | 0.00399 | 0 | 0 |
Changes in Working Capital | -1.23864 | 0.83378 | -0.42562 | 0.08378 | 0.04725 |
Cash From Financing Activities | 4.50908 | 14.1342 | 10.2598 | 1.16098 | 0.22274 |
Financing Cash Flow Items | 0 | -0.045 | 0 | 0.47048 | 0 |
Issuance (Retirement) of Stock, Net | 4.98657 | 14.2222 | 10.2948 | 0.3905 | 0.10092 |
Issuance (Retirement) of Debt, Net | -0.47749 | -0.04308 | -0.035 | 0.3 | 0.12183 |
Net Change in Cash | -9.03498 | 6.79821 | 6.68616 | 0.44459 | 0.11054 |
Cash From Operating Activities | 0.01307 | 0.0111 | 0.00196 | ||
Cash From Investing Activities | -0.00575 | -0.01795 | -0.02012 | ||
Capital Expenditures | -0.00575 | -0.01795 | -0.02012 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -2.78434 | -14.0366 | -11.2414 | -7.42708 | -3.6134 |
Cash From Operating Activities | -3.0772 | -13.5383 | -10.3015 | -8.30599 | -3.30805 |
Cash From Operating Activities | 0.00338 | 0.01307 | 0.00958 | 0.00621 | 0.003 |
Non-Cash Items | 0.33669 | 1.72384 | 1.40694 | 0.90029 | 0.43068 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Cash Interest Paid | 0.00288 | 0.00977 | 0.00721 | 0.00721 | 0.00421 |
Changes in Working Capital | -0.63292 | -1.23864 | -0.4766 | -1.78541 | -0.12833 |
Cash From Investing Activities | 0 | -0.00575 | -0.00367 | -0.00367 | -0.00367 |
Capital Expenditures | 0 | -0.00575 | -0.00367 | -0.00367 | -0.00367 |
Cash From Financing Activities | 10.5132 | 4.50908 | 4.59191 | 1.15574 | 0.34743 |
Issuance (Retirement) of Stock, Net | 10.6284 | 4.98657 | 4.98657 | 1.41745 | 0.47759 |
Issuance (Retirement) of Debt, Net | -0.11522 | -0.47749 | -0.39466 | -0.26171 | -0.13016 |
Net Change in Cash | 7.43598 | -9.03498 | -5.71327 | -7.15392 | -2.96429 |
Financing Cash Flow Items | 0 | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
CNS Pharmaceuticals, Inc. Company profile
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals Inc. is a clinical pharmaceutical company. The Company is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The Company is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 48% to $14M. Higher net loss reflects Research and development increase of 85% to $9.3M (expense), Selling/General/Admin Expense increase of 7% to $4.7M (expense), Interest expense increase from $3K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.57 to -$0.53.
Industry: | Biotechnology & Medical Research (NEC) |
2100 West Loop S Ste 900
HOUSTON
TEXAS 77027-3522
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com